Skip to content

    Taysha Gene Therapies (TSHA) stock price & financials

    View TSHA earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+94.3% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $1.79M
    $2.02M
    $2.30M
    $1.99M
    $0
    -100.0%
    $5.49M
    +171.3%
    $0
    -100.0%
    $0
    -100.0%
    Weakening
    Operating Profit
    -$25.90M
    -$19.93M
    -$21.42M
    -$26.75M
    -$34.02M
    -31.4%
    -$28.30M
    -42.0%
    -$43.49M
    -103.0%
    -$47.35M
    -77.0%
    Weakening
    Net Profit
    -$25.52M
    -$18.79M
    -$21.53M
    -$26.88M
    -$32.73M
    -28.2%
    -$27.85M
    -48.3%
    -$42.41M
    -97.0%
    -$46.64M
    -73.5%
    Weakening
    EPS
    $-0.10
    $-0.08
    $-0.09
    $-0.09
    +10.0%
    $-0.12
    -50.0%
    $-0.13
    -44.4%
    Weakening
    Other Income
    $374.0K
    $1.15M
    -$108.0K
    -$129.0K
    $1.29M
    +245.2%
    $449.0K
    -60.9%
    $1.08M
    $710.0K
    Weakening
    Interest
    $24.0K
    $22.0K
    $19.0K
    $17.0K
    $15.0K
    -37.5%
    $12.0K
    -45.5%
    $9.0K
    -52.6%
    $6.0K
    -64.7%
    Weakening
    Depreciation
    Profit before Tax
    MarginsOPM
    -1448.4%
    -985.8%
    -930.5%
    -1347.1%
    -516.0%
    +47.7%
    Strengthening
    Tax
    ReturnsROIC
    3.2%
    2.3%
    2.7%
    3.4%
    4.1%
    +28.2%
    3.5%
    +48.3%
    5.3%
    +97.0%
    5.8%
    +73.5%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$251.25M$149.10M$87.88M$143.94M$139.04M$319.77M$455.41M
    Short-Term Investments
    Total Current Assets$257.88M$159.60M$96.42M$149.87M$142.13M$324.65M$461.43M
    Net PP&E$287.0K$50.61M$25.91M$20.41M$15.87M$16.18M$8.73M
    Goodwill
    Intangibles
    Total Assets$258.88M$213.96M$126.28M$172.73M$160.36M$343.32M$470.43M
    LiabilitiesTotal Current Liabilities$7.13M$51.75M$62.79M$36.76M$26.23M$26.55M$25.98M
    Short-Term Debt
    Long-Term Debt$37.19M$37.97M$40.51M$43.94M$50.11M$49.26M
    Long-Term Leases$20.44M$18.95M$17.36M$18.17M$6.29M
    Total Liabilities$7.58M$118.57M$125.33M$97.79M$88.84M$96.38M$83.17M
    EquityCommon Stock & APIC$1.0K$2.0K$2.0K$3.0K$3.0K
    Retained Earnings-$61.13M-$235.65M-$401.44M-$513.01M-$602.30M-$711.30M-$800.35M
    Total Equity$251.30M$95.38M$949.0K$74.94M$71.53M$246.94M$387.27M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating-$30.73M-$117.04M-$88.39M-$73.02M-$81.22M-$93.09M-$132.19M
    Cash from Investing-$9.08M-$21.55M-$24.93M-$7.35M-$363.0K-$604.0K-$3.32M
    Cash from Financing$291.06M$39.08M$52.10M$136.39M$76.68M$274.59M$275.72M
    SummaryCapital Expenditure-$82.0K-$15.30M-$20.62M-$3.87M-$374.0K-$738.0K-$381.0K
    Free Cash Flow-$30.81M-$132.35M-$109.01M-$76.89M-$81.60M-$93.83M-$132.57M
    FCF Margin-4356.9%-497.6%-979.2%-960.1%-2417.0%

    Ratios